Journal Information
Vol. 46. Issue S4.
HEMO 2024
Pages S445 (October 2024)
Vol. 46. Issue S4.
HEMO 2024
Pages S445 (October 2024)
Full text access
MOLECULAR CYTOGENETIC CHARACTERIZATION OF DER(7)T(1;7) IN MYELODYSPLASTIC SYNDROME: CLINICAL IMPLICATIONS
Visits
422
GF Lima, BF Silva, IC Gonçalves, L Otero, MM Rocha, VL Lovatel, TS Fernandez
Cytogenetic Laboratory, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 46. Issue S4

HEMO 2024

More info
Introduction

Myelodysplastic syndrome (MDS) represents a heterogeneous group of hematologic malignancies characterized by ineffective hematopoiesis, resulting in cytopenias and a high risk of progression to acute myeloid leukemia (AML). Approximately 50% of patients with MDS have chromosomal abnormalities, which are a prognostic marker. The most common chromosomal abnormalities in MDS include deletion of the long arm of chromosome 5 [del(5q)], alterations in chromosome 7 (deletion of the long arm of chromosome 7 [del(7q)]/monosomy 7), and trisomy 8. Alterations in chromosome 7 are associated with an unfavorable prognosis. The chromosomal abnormalities [-7/del(7q)] affect genes critical for cellular regulation, leading to dysfunctions in the development and maturation of blood cells. The unbalanced translocations der(7)t(1;7) has been considered by some studies as a variant of chromosome 7 alterations, presenting a prognosis similar to these alterations. However, according to the Revised International Prognostic Scoring System (IPSS-R), the der(7)t(1;7) presents an intermediate prognosis.

Objective

To report cases of patients with MDS who presented the unbalanced translocations der(7)t(1;7) and their clinical outcomes.

Materials and methods

This study included 4 patients of a total of 460 adult patients with MDS, between 2000-2023. Cytogenetic analyses were performed on bone marrow cells by G-banding and fluorescence in situ hybridization (FISH).

Results

Chromosomal abnormalities were observed in 41% (190/460) of the patients. Of these patients, four had unbalanced translocations involving chromosomes 1 and 7. The patients were classified in advanced subtypes (MDS-AB1/AB2) and progressed to AML. Of these patients, three had der(7)t(1;7)(q10;q10) and one patient had a different breakpoint region [46,XY,der(7)t(1;7)(q21;q31)]. Not previously reported in the literature.

Discussion

Although uncommon, unbalanced translocation involving the der(7)t(1;7)(q10;q10) breakpoints has been previously reported in approximately 0.6% to 2.6% of MDS cases. Some studies suggest that der(7)t(q10;p10) is associated with a more favorable prognosis compared with -7/del(7q), while others have not observed significant differences in prognosis between these cytogenetic alterations. In our study, we observed that these chromosomal translocations were associated with advanced disease subtypes and progression to AML.

Conclusion

Our study suggests that der(7)t(1;7) is associated with an unfavorable clinical outcome in adult patients with MDS.

Support

Ministério da Saúde – INCA.

Full text is only available in PDF
Download PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools